Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells $7,429,230.00 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 495,282 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the transaction, the chief executive officer owned 253,071 shares of the company's stock, valued at approximately $3,796,065. The trade was a 66.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI traded up $0.17 during mid-day trading on Monday, reaching $14.69. 1,137,529 shares of the company's stock traded hands, compared to its average volume of 1,139,354. The business has a 50-day simple moving average of $14.25 and a 200 day simple moving average of $16.54. The stock has a market cap of $2.13 billion, a P/E ratio of -5.50 and a beta of 1.33. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter last year, the business posted ($0.68) earnings per share. Equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DNLI has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Bank of America decreased their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Wedbush cut their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $33.71.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of DNLI. Sterling Capital Management LLC boosted its holdings in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after purchasing an additional 1,551 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Denali Therapeutics during the first quarter worth about $41,000. GF Fund Management CO. LTD. purchased a new position in Denali Therapeutics during the fourth quarter worth about $62,000. Finally, Point72 Hong Kong Ltd bought a new stake in Denali Therapeutics in the 4th quarter worth about $65,000. Hedge funds and other institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.